Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.

Up 23%: Time to Buy Exelixis?

Exelixis  (NASDAQ: EXEL  ) had a great day in the market today, up 23% on the news that its drug cobimetinib in combination with Roche's  (NASDAQOTH: RHHBY  ) drug Zelboraf succeeded in a phase 3 trial's primary endpoint of extending progression-free survival.

Of course, cobimetinib isn't all investors should think about regarding Exelixis: Cometriq will also be important. In the video below, health care analysts Michael Douglass and David Williamson give their take on Exelixis.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


Read/Post Comments (2) | Recommend This Article (8)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On July 14, 2014, at 7:30 PM, DNAstock wrote:

    Michael, dude, if you're going to be talking about this stuff, at least learn how to pronounce the words.

    B-raf (pronunciation: bee-raf, not "braf")

    Gemcitabine (pronunciation: jem-SITE-a-been)

    Cobimetinib (pronunciation: ko-bee-met-tin-ib)

  • Report this Comment On July 15, 2014, at 3:35 PM, TepperMay wrote:

    William Blair Reiterates Outperform On Exelixis Following Positive Phase 3 Results

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3028610, ~/Articles/ArticleHandler.aspx, 5/22/2015 7:46:14 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Apple's next smart device (warning, it may shock you

Apple recently recruited a secret-development "dream team" to guarantee its newest smart device was kept hidden from the public for as long as possible. But the secret is out. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early-in-the-know investors. To be one of them, and see Apple's newest smart gizmo, just click here!